Back to School: How biopharma can reboot drug development. Access exclusive analysis here

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

Atara follows Phase I MS data with $178M offering
Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $175.5 million in a follow-on a day after reporting Phase I data ATA188 reduced disability in multiple sclerosis patients. The company’s ATA188, an allogeneic EBV-specific T cell therapy, led to dose-dependent sustained disability improvement

Read the full 473 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers